Filing Analysis
Daxor Corporation held its Annual Meeting of Shareholders on June 23, 2026. The meeting resulted in the election of six directors and the ratification of Bush & Associates, CPA as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 23, 2026.
- Six directors elected: Henry D. Cremisi, MD; Edward Feuer; Joy Goudie, Esq.; Michael Feldschuh; Jonathan Feldschuh; and Caleb DesRosiers, Esq.
- Bush & Associates, CPA was ratified as the independent registered public accounting firm with 4,423,295 votes in favor.
Daxor Corporation completed a registered direct offering of 765,958 common shares at $11.75 per share, raising approximately $8.14 million in net proceeds.
🚩 Red Flags
- Potential dilution for existing shareholders due to the issuance of new common stock.
📋 Key Facts
- Issued and sold 765,958 registered shares of common stock.
- Offering price: $11.75 per share.
- Net proceeds (after fees/expenses): approximately $8,142,006.
- Closing date: January 26, 2026.
- Placement agent: Lake Street Capital Markets, LLC.
- Shares were registered under a shelf registration statement (File No. 333-281622) effective Jan 20, 2026.
Daxor Corporation filed an 8-K to provide an updated investor presentation via Exhibit 99.1. The filing contains no material changes to operations, financial position, or corporate governance.
📋 Key Facts
- The company released a new investor presentation on January 23, 2026.
- No specific financial metrics or strategic shifts were disclosed in the text of the 8-K itself.
Daxor Corporation held its Annual Meeting of Shareholders on July 15, 2024. The meeting resulted in the election of six directors and the ratification of Citrin Cooperman, LLP as the company's independent registered public accounting firm.
📋 Key Facts
- Annual Meeting held on July 15, 2024.
- Six directors elected: Henry D. Cremisi, MD; Edward Feuer; Joy Goudie, Esq.; Michael Feldschuh; Jonathan Feldschuh; and Caleb DesRosiers, Esq.
- Citrin Cooperman, LLP was ratified as the independent registered public accounting firm with 4,759,964 votes in favor.
Daxor Corporation reported that Nasdaq had previously issued a notice of non-compliance regarding audit committee requirements following the death of a committee member. The matter is now resolved as Nasdaq has confirmed the company's compliance following the appointment of Caleb DesRosiers.
🚩 Red Flags
- Previous failure to meet Nasdaq listing standards (audit committee composition).
📋 Key Facts
- Nasdaq notified the company of non-compliance with Listing Rule 5605 due to the passing of Mr. James A. Lombard on October 17, 2023.
- The non-compliance related specifically to audit committee requirements.
- Caleb DesRosiers was appointed to the audit committee to restore compliance.
- Nasdaq Staff has determined the company is now in compliance and the matter is closed.
Daxor Corporation has entered into a definitive agreement to acquire exclusive worldwide rights and intellectual property for Volumex and Megatope from its supplier, Iso-Tex Diagnostics, Inc. Additionally, the company acquired exclusive rights to Glofil, a drug used for measuring glomerular filtration rate (GFR).
🚩 Red Flags
- Transaction with an existing supplier can sometimes indicate supply chain dependency issues, though here it appears to be an integration move.
📋 Key Facts
- Acquisition of exclusive/worldwide IP for Volumex and Megatope from Iso-Tex Diagnostics, Inc.
- Acquisition of exclusive rights to Glofil (a GFR measurement drug) previously sold by Iso-Tex.
- The deal involves transitioning manufacturing rights from a supplier to the company's direct control or ownership.
Daxor Corporation announced the submission of its next-generation blood volume analyzer (Daxor BVA) to the FDA via a dual 510(k)/CLIA-waiver pathway. The company expects potential regulatory clearance during the first half of 2024.
📋 Key Facts
- Submitted Daxor BVA for FDA clearance on January 2, 2024.
- Submission utilizes a dual 510(k)/CLIA-waiver pathway.
- Anticipated regulatory outcome/clearance expected in H1 2024.